Am J Psychiatry 155:1521-1528, November 1998
©Copyright 1998 American Psychiatric Association
Prospective Study of Tardive Dyskinesia in the Elderly: Rates and Risk Factors
Margaret G. Woerner, Ph.D.,
Jose Ma. J. Alvir, Dr.P.H.,
Bruce L. Saltz, M.D.,
Jeffrey A. Lieberman, M.D., and
John M. Kane, M.D.
Objective:The purposes of this study were to investigate the rate (incidence) of tardive dyskinesia in elderly patients beginning treatment with antipsychotic medication and to identify risk factors for development of tardive dyskinesia in this age group. Method:A group of 261 neuroleptic-naive patients aged 55 or above were identified at the time they were starting antipsychotic drug treatment. This group is the complete study group; a preliminary report based on the first 160 patients was published previously. Patients were evaluated at baseline and followed up at 3-month intervals for periods ranging from 3 to 393 weeks. Assessments included abnormal involuntary movements, extrapyramidal signs, psychiatric symptoms, and medical and drug treatment histories.Results:The cumulative rates of tardive dyskinesia were 25%, 34%, and 53% after 1, 2, and 3 years of cumulative antipsychotic treatment. A greater risk of tardive dyskinesia was associated with history of ECT treatment, higher mean daily and cumulative antipsychotic doses, and presence of extrapyramidal signs early in treatment. Differences in tardive dyskinesia rates between diagnostic groups found in univariate analyses were attenuated when the authors controlled for these variables.Conclusions:Tardive dyskinesia rates for patients beginning treatment with conventional antipsychotics in their fifth decade or later are three to five times what has been found for younger patients, despite treatment with lower doses. Alternative treatments need to be investigated. Am J Psychiatry 1998; 155: 1521-1528
This article has been cited by other articles:
|
|
|
|
 
C. Kenney, C. Hunter, A. Davidson, and J. Jankovic
Metoclopramide, an Increasingly Recognized Cause of Tardive Dyskinesia
J. Clin. Pharmacol.,
March 1, 2008;
48(3):
379 - 384.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tzimos, V. Samokhvalov, M. Kramer, L. Ford, C. Gassmann-Mayer, P. Lim, and M. Eerdekens
Safety and Tolerability of Oral Paliperidone Extended-Release Tablets in Elderly Patients With Schizophrenia: A Double-Blind, Placebo-Controlled Study With Six-Month Open-Label Extension
Am J Geriatr Psychiatry,
January 1, 2008;
16(1):
31 - 43.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Claxton, J. J. Chen, and D. M. Swope
Drug-Induced Movement Disorders
Journal of Pharmacy Practice,
December 1, 2007;
20(6):
415 - 429.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. A. Rosenheck, D. L. Leslie, J. L. Sindelar, E. A. Miller, P. N. Tariot, K. S. Dagerman, S. M. Davis, B. D. Lebowitz, P. Rabins, J. K. Hsiao, et al.
Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease
Arch Gen Psychiatry,
November 1, 2007;
64(11):
1259 - 1268.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Damier, S. Thobois, T. Witjas, E. Cuny, P. Derost, S. Raoul, P. Mertens, J.-C. Peragut, J.-J. Lemaire, P. Burbaud, et al.
Bilateral Deep Brain Stimulation of the Globus Pallidus to Treat Tardive Dyskinesia
Arch Gen Psychiatry,
February 1, 2007;
64(2):
170 - 176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Kane
Tardive Dyskinesia Circa 2006
Am J Psychiatry,
August 1, 2006;
163(8):
1316 - 1318.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Tenback, P. N. van Harten, C. J. Slooff, J. van Os, and SOHO Study Group
Evidence That Early Extrapyramidal Symptoms Predict Later Tardive Dyskinesia: A Prospective Analysis of 10,000 Patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) Study
Am J Psychiatry,
August 1, 2006;
163(8):
1438 - 1440.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Stueber and C. M. Swartz
Carvedilol suppresses intractable hiccups.
J Am Board Fam Med,
July 1, 2006;
19(4):
418 - 421.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. REMINGTON
Rational pharmacotherapy in early psychosis
The British Journal of Psychiatry,
August 1, 2005;
187(48):
s77 - s84.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. U. CORRELL, J. M. KANE, and S. LEUCHT
Dr. Correll and Colleagues Reply
Am J Psychiatry,
February 1, 2005;
162(2):
405 - 406.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. A. Nasrallah and A. T. Nasrallah
Nasrallah and Nasrallah Respond
Am J Geriatr Psychiatry,
December 1, 2004;
12(6):
659 - 660.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. U. Correll, S. Leucht, and J. M. Kane
Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies
Am J Psychiatry,
March 1, 2004;
161(3):
414 - 425.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Boyd
Atypical Antipsychotics: Impact on Overall Health and Quality of Life
Journal of the American Psychiatric Nurses Association,
August 1, 2002;
8(4_suppl):
S9 - S17.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. S. Schneider, P. N. Tariot, C. G. Lyketsos, K. S. Dagerman, K. L. Davis, S. Davis, J. K. Hsiao, D. V. Jeste, I. R. Katz, J. T. Olin, et al.
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer Disease Trial Methodology
Am J Geriatr Psychiatry,
November 1, 2001;
9(4):
346 - 360.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. S. Meyers, S. A. Klimstra, M. Gabriele, M. Hamilton, T. Kakuma, F. Tirumalasetti, and G. S. Alexopoulos
Continuation Treatment of Delusional Depression in Older Adults
Am J Geriatr Psychiatry,
November 1, 2001;
9(4):
415 - 422.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Tardive Dyskinesia in the Elderly
Journal Watch (General),
November 20, 1998;
1998(1120):
2 - 2.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1998
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
